Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
Clearside Biomedical (NASDAQ: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has scheduled the release of its first quarter 2025 financial results for Wednesday, May 14, 2025, after market close. The company has noted that it will not hold a conference call this quarter. Investors can access quarterly results and other investor-related information through the Investors section of Clearside's website.
Clearside Biomedical (NASDAQ: CLSD), un'azienda biofarmaceutica specializzata nella somministrazione di terapie alla parte posteriore dell'occhio tramite lo spazio suprachoroideo (SCS®), ha programmato la pubblicazione dei suoi risultati finanziari del primo trimestre 2025 per mercoledì 14 maggio 2025, dopo la chiusura del mercato. L'azienda ha comunicato che in questo trimestre non terrà una conference call. Gli investitori possono consultare i risultati trimestrali e altre informazioni rilevanti nella sezione Investors del sito web di Clearside.
Clearside Biomedical (NASDAQ: CLSD), una compañía biofarmacéutica centrada en la entrega de terapias a la parte posterior del ojo a través del espacio supracoroideo (SCS®), ha programado la publicación de sus resultados financieros del primer trimestre de 2025 para el miércoles 14 de mayo de 2025, después del cierre del mercado. La compañía ha indicado que no realizará una llamada de conferencia este trimestre. Los inversores pueden acceder a los resultados trimestrales y otra información relacionada a través de la sección de Inversores en el sitio web de Clearside.
Clearside Biomedical (NASDAQ: CLSD)는 후안방 공간(SCS®)을 통해 눈 뒤쪽에 치료제를 전달하는 데 중점을 둔 생명공학 제약 회사로, 2025년 1분기 재무 결과를 2025년 5월 14일 수요일 장 마감 후에 발표할 예정입니다. 회사는 이번 분기에는 컨퍼런스 콜을 진행하지 않을 것이라고 밝혔습니다. 투자자들은 Clearside 웹사이트의 투자자 섹션을 통해 분기별 실적 및 기타 투자자 관련 정보를 확인할 수 있습니다.
Clearside Biomedical (NASDAQ : CLSD), une société biopharmaceutique spécialisée dans la délivrance de thérapies à l'arrière de l'œil via l'espace suprachoroïdien (SCS®), a prévu la publication de ses résultats financiers du premier trimestre 2025 pour le mercredi 14 mai 2025, après la clôture du marché. La société a précisé qu'elle ne tiendra pas de conférence téléphonique ce trimestre. Les investisseurs peuvent consulter les résultats trimestriels et d'autres informations liées aux investisseurs dans la section Investors du site web de Clearside.
Clearside Biomedical (NASDAQ: CLSD), ein biopharmazeutisches Unternehmen, das sich auf die Verabreichung von Therapien an den hinteren Teil des Auges durch den suprachoroidalen Raum (SCS®) spezialisiert hat, hat die Veröffentlichung seiner Finanzergebnisse für das erste Quartal 2025 für Mittwoch, den 14. Mai 2025 nach Börsenschluss geplant. Das Unternehmen hat mitgeteilt, dass in diesem Quartal keine Telefonkonferenz stattfinden wird. Investoren können die Quartalsergebnisse und weitere investorenbezogene Informationen über den Investor-Bereich auf der Website von Clearside abrufen.
- None.
- None.
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter.
Information about the Company’s quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company’s website.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
Source: Clearside Biomedical, Inc.
FAQ
When will Clearside Biomedical (CLSD) release Q1 2025 earnings?
Will Clearside Biomedical (CLSD) host an earnings call for Q1 2025?
Where can investors find Clearside Biomedical's (CLSD) Q1 2025 financial results?
What is Clearside Biomedical's (CLSD) main business focus?
